Yescarta (axicabtagene ciloleucel)

pCPA File Number: 22285

Negotiation Status:

Concluded with an LOI

Indication(s):

Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CDA-AMC Project Number:

PG0293

pCPA Engagement Letter Issued:

2023-09-26

Negotiation Process Concluded:

2024-09-06